Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

Liu D, Lu M, Li J et al (2016) The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol 14:305. https://doi.org/0.1186/s12957-016-1042-y

Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27–40. https://doi.org/10.1016/S0140-6736(21)00797-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang YK, Chen LT, Ryu MH et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23:234–247. https://doi.org/10.1016/S1470-2045(21)00692-6

Article  CAS  PubMed  Google Scholar 

Bigot F, Castanon E, Baldini C et al (2017) Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy immune score (GRIm-score). Eur J Cancer 84:212–218. https://doi.org/10.1016/j.ejca.2017.07.027

Article  CAS  PubMed  Google Scholar 

Minami S, Ihara S, Ikuta S, Komuta K (2019) Gustave Roussy immune score and Royal Marsden Hospital prognostic score are biomarkers of immune-checkpoint inhibitor for non-small cell lung cancer. World J Oncol 10:90–100. https://doi.org/10.14740/wjon1193

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lenci E, Cantini L, Pecci F (2021) The Gustave Roussy immune (GRIm)-score variation is an early-on-treatment biomarker of outcome in advanced non-small cell lung cancer (NSCLC) patients treated with first-line pembrolizumab. J Clin Med 10:1005. https://doi.org/10.3390/jcm10051005

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minami S, Ihara S, Komuta K (2019) Gustave Roussy immune score is a prognostic factor for chemotherapy-naive pulmonary adenocarcinoma with wild-type epidermal growth factor receptor. World J Oncol 10:55–61. https://doi.org/10.14740/wjon1184

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakazawa N, Sohda M, Ubukata Y et al (2022) Changes in the Gustave Roussy immune score as a powerful prognostic marker of the therapeutic sensitivity of nivolumab in advanced gastric cancer: a multicenter, retrospective study. Ann Surg Oncol 29:7400–7406. https://doi.org/10.1245/s10434-022-12226-4

Article  PubMed  Google Scholar 

Gregory AD, Houghton AM (2011) Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71:2411–2416. https://doi.org/10.1158/0008-5472.CAN-10-2583

Article  CAS  PubMed  Google Scholar 

Grimm M, Feyen O, Hofmann H et al (2016) Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue. Tumour Biol 37:3807–3816. https://doi.org/10.1007/s13277-015-4224-2

Article  CAS  PubMed  Google Scholar 

Motomura T, Shirabe K, Mano Y et al (2013) Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 58:58–64. https://doi.org/10.1016/j.jhep.2012.08.017

Article  CAS  PubMed  Google Scholar 

Wei C, Yang C, Wang S et al (2019) M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22/PI3K/AKT signaling. Onco Targets Ther 12:3051–3063. https://doi.org/10.2147/OTT.S198126

Article  CAS  PubMed  PubMed Central  Google Scholar 

Su P, Jiang L, Zhang Y et al (2022) Crosstalk between tumor-associated macrophages and tumor cells promotes chemoresistance via CXCL5/PI3K/AKT/mTOR pathway in gastric cancer. Cancer Cell Int 22:290. https://doi.org/10.1186/s12935-022-02717-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pençe HH, Gündeş E, Senger AS et al (2019) Prognostic significance of preoperative serum lactate dehydrogenase in patients with resectable gastric adenocarcinoma. Int J Clin Exp Med 12:2746–2752

Google Scholar 

Petrelli F, Cabiddu M, Coinu A et al (2015) Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol 54:961–970. https://doi.org/10.3109/0284186X.2015.1043026

Article  CAS  PubMed  Google Scholar 

Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E (2008) The antioxidant properties of serum albumin. FEBS Lett 582:1783–1787. https://doi.org/10.1016/j.febslet.2008.04.057

Article  CAS  PubMed  Google Scholar 

Nie X, Xu T, Zhang L, Cheng W (2024) The Gustave Roussy immune score as a novel scoring system for predicting platinum resistance in advanced high-grade serous ovarian cancer. Eur J Obstet Gynecol Reprod Biol 294:97–104. https://doi.org/10.1016/j.ejogrb.2024.01.002

Article  PubMed  Google Scholar 

Shangguan J, Huang X, Liu X et al (2023) Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study. Front Oncol 13:1195499. https://doi.org/10.3389/fonc.2023.1195499

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hatanaka T, Naganuma A, Hiraoka A et al (2023) The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: a multicenter retrospective analysis. Cancer Med 12(4):4259–4269. https://doi.org/10.1002/cam4.5294

Article  CAS  PubMed  Google Scholar